Leqembi Authorized for Early Alzheimer's Disease in Great Britain

Leqembi Authorized for Early Alzheimer's Disease in Great Britain. In Great Britain, lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) in adult patients that are apolipoprotein E ?4 (ApoE ?4)* heterozygotes or non-carriers(1)